Macrogenomic Event Detection in Solid Tumors
Working Group Charter
Clinical implementation of technologies utilized for macrogenomic event detection in solid tumors
Work Product Category
Manuscript or Publication: Statement of Clinical Utility
Specific Aims for the Work Product
- Outline technologies that are currently available clinically for macrogenomic event detection in solid tumors. This would include an overview of:
- Technical considerations
- Clinical considerations
- Make comparisons between each technology, highlighting what they are able to detect as well as their limitations.
- Discuss ease of test implementation.
- Give an overall assessment of clinical utility (first-line vs. second-line test depending on expected findings/tumor type).
To educate clinical laboratories about the implementation of available technologies for macrogenomic event (copy number variant, structural variants, CN-LOH, etc.) detection. This would include information regarding sample requirements and perceived pros/cons of each technology from initial startup to analysis and data storage.
Working Group Members
Lisa Lansdon
Children's Mercy Kansas City
Cynthia Chow
University of Texas MD Anderson Cancer Center
Laveniya Satgunaseelan
University of Utah
Xiangqiang Shao
London Health Sciences Center
Gocke Toruner
Columbia University Irving Medical Center
Trevor Pugh
Ontario Institute for Cancer Research
University of Toronto